US2017258914A1PendingUtilityA1
Novel antifungal composition
Est. expiryFeb 11, 2031(~4.6 yrs left)· nominal 20-yr term from priority
Inventors:Ake Lindahl
A61P 31/10A61P 17/00A61K 47/20A61K 31/13A61K 47/183A61K 47/10A61K 31/137A61K 47/12A61K 9/0014A61K 47/14A61K 31/00A61K 31/19A61K 9/08A61K 2121/00A61K 47/18
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
There is provided a pharmaceutical composition for the treatment of fungal infection of the nail comprising a anti-fungal allylamine compound present in an amount of about 10%, an organic acid or an ester thereof, a diol and a sequestering agent where the pharmacological composition is essentially water-free
Claims
exact text as granted — not AI-modified1 - 12 . (canceled)
13 . A method of treatment of fungal infection of a callous wherein a pharmaceutical composition is administered to the callous of a patient, wherein the pharmaceutical composition comprises terbinafine present in an amount of more than 5%, an organic acid or an ester thereof present in an amount of 1 to 30%, a diol present in an amount of about 50 to 95% and EDTA present in an amount of 0.01 to 5%, said pharmaceutical composition being essentially water-free; wherein:
said diol is one or more selected from the group consisting of propanediol, butanediol, pentanediol, and hexanediol; said organic acid is one or more selected from the group consisting of saturated or unsaturated, straight or branched, aliphatic mono-, di- or poly-carboxylic acids having 1-8 carbon atoms, araliphatic dicarboxylic acids having 1-8 carbon atoms, aromatic dicarboxylic acids having 1-8 carbon atoms, oxy-carboxylic acids having 1-8 carbon atoms, and hydroxyl-carboxylic acids having 1-8 carbon atoms; and said ester of the organic acid is one or more C 1-4 alkyl esters of said organic acid.
14 . A pharmaceutical composition for the treatment of onychomycosis of the nail comprising terbinafine present in an amount of more than 5%, an organic acid or an ester thereof present in an amount of 1 to 30%, a diol present in an amount of about 50 to 95% and EDTA present in an amount of 0.01 to 5%, said pharmaceutical composition being essentially water-free; wherein:
said diol is one or more selected from the group consisting of propanediol, butanediol, pentanediol, and hexanediol; said organic acid is one or more selected from the group consisting of saturated or unsaturated, straight or branched, aliphatic mono-, di- or poly-carboxylic acids having 1-8 carbon atoms, araliphatic dicarboxylic acids having 1-8 carbon atoms, aromatic dicarboxylic acids having 1-8 carbon atoms, oxy-carboxylic acids having 1-8 carbon atoms, and hydroxyl-carboxylic acids having 1-8 carbon atoms; and said ester of the organic acid is one or more C 1-4 alkyl esters of said organic acid.
15 . The composition according to claim 14 , wherein the antifungal allylamine compound is dissolved in the composition.
16 . The composition according to claim 14 , wherein the organic acid is lactic acid.
17 . The composition according to claim 14 , wherein the organic acid or ester thereof is present in an amount of 5% to 25%.
18 . The composition according to claim 14 , wherein the allylamine antifungal compound is present in an amount of from 5% to 12%.
19 . The composition according to claim 18 , wherein the allylamine antifungal compound is present in an amount of from 8% to 11.5%.
20 . The composition according to claim 14 , comprising lactic acid in an amount of 5% to 25%; a diol selected from the group consisting of propanediol, butanediol, pentanediol and hexanediol in an amount of about 50 to 95% terbinafine in an amount of from 5% to 12%; and EDTA in an amount between 0.03% and 1%.
21 . The composition according to claim 14 , comprising from about 67.5% to about 84% of propandiol, from 8% to 20% of lactic acid, from 0.03% to 0.1% EDTA and from 8% to 12% of terbinafine.
22 . A method of treatment of onychomycosis of the nail wherein a composition according to claim 14 , is administered to the nail of a patient.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.